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LETTERS TO THE EDITORRegarding “Cost-effectiveness analysis of elective
endovascular repair compared with open surgical
repair of abdominal aortic aneurysms for patients
at a high surgical risk: A 1-year patient-level
analysis conducted in Ontario, Canada”
A 1-year economic evaluation study comparing endovascular
aneurysm repair (EVAR) with open surgical repair (OSR) for the
management of abdominal aortic aneurysms (AAAs) in patients at a
high surgical risk supported that EVAR may be a cost-effective ther-
apeutic option for high-risk patients undergoing elective AAA repair
(total average 1-year costs: $34,146 vs. $34,170, respectively;Pnot
significant).1 Compared with OSR, EVAR was associated with lower
initial hospitalization costs ($31,181 vs. $28,139, respectively; P 
not significant) but significantly higher follow-upmedical expenses at
1 year ($2,171 vs. $5,172, respectively, P .05).1
A possible limitation that may lead to the support of incorrect
and/or biased conclusions is the duration of this study (1 year).1
This may already be suspected from the comparison of the 1-year
follow-up medical expenses; although the initial hospitalization
expenses were not significantly different for the 2 procedures,
EVAR had considerably higher 1-year follow-up costs.1
The cost-effectiveness of EVAR may be hampered by the
development of long-term complications (e.g. endoleaks, stent
migrations, graft-limb thromboses, and graft stenoses).2 An exten-
sive systematic review and comparative assessment of the 2 proce-
dures for the elective repair of AAAs showed that a large percentage
of the complications following EVAR occurs after the first year.2
For example, although the incidence of type I endoleaks at 1 year was
3.5% (range, 0-14%; 13 studies [n  2,544 patients]), the same
incidence rose to 6.7% (range, 0%-21.5%) beyond the first year (18
studies [n 7,848 patients]).2 Similar results were reported for stent
migration rates; although the 1-year stent migration rate was1% (3
studies [n1,599 patients]), 4.4% of the patients demonstrated stent
migration1 year following EVAR (range, 1.7%-18.9%; 8 studies [n
 7,027 patients)].2 Finally, whereas the 1-year incidence of graft-
limb thrombosis was 2.5% (range, 0%-11%; 11 studies [n  1,657
patients]), this incidence increased to 3.8% (range, 1.9%-6.1%; 8
studies [n 6,602 patients]) after the first year.2
Another issue which increases the long-term costs of EVAR is
the need for long-term (if not life-long) surveillance.3 A study
comparing the follow-up costs of patients undergoing EVAR vs.
OSR for elective AAA repair showed that not only is EVAR more
expensive at the 1-year follow-up ($17,640 vs. $14,122, respec-
tively; P .001), but also that this cost discrepancy increases with
a longer follow-up period (average follow-up cost per year: $999
vs. $55, respectively; P  .001).3
In high-risk patients undergoing elective AAA repair, EVAR is
probably associated with improved mortality rates compared with
OSR (1-year all-cause mortality rates: 7.1% vs. 17.3%, respectively;
P  .04).1 However, there is compelling evidence2-4 suggesting
that, after taking into consideration the need for long-term surveil-
lance, EVAR may not be as cost-effective as OSR for the manage-
ment of patients undergoing elective AAA repair, including those
individuals at a high surgical risk.
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Reply
In this 1-year Canadian study among high-risk patients, the
1-year medical costs were similar between endovascular aneurysm
repair (EVAR) and open surgical repair (OSR) ($33,311 vs
$33,352, respectively) while the 1-year mortality rates were signif-
icantly lower in EVAR patients (7.1% vs 17.3%). Based on boot-
strap techniques to deal with sampling uncertainty, the probability
of EVAR being cost-effective was 0.76 and 0.9 if society was
willing to spend $50,000 per life year gained (LYG) or $100,000/
LYG, respectively.1
In a sensitivity analysis, we extrapolated the 1-year mortality
rate observed in our trial to a 5-year time horizon. We assumed
long-term routine follow-up costs to EVAR only and several
re-intervention rates (5%, 10%, and 20%) in EVAR patients to
reflect an increased risk of long-term complications following
EVAR. We also used different assumptions regarding mortality
convergence. In the least favorable scenario (convergence of mor-
tality rate at 2 years and re-intervention rate of 20%), the incremen-
tal cost-effectiveness ratio of EVAR compared with OSR in high-
risk patients was $14,968/LYG and $38,720/QALY. Based on
these results, we concluded that “EVAR may be a cost-effective
strategy in high-risk patients.” Our conclusion also stated that
“longer term data are needed to decrease the uncertainty associ-
ated with the results”.1
We agree with Dr Paraskevas that it is very important to model
the long-term costs and consequences associated with EVAR and
OSR. We recognize, as outlined in the discussion, that our extrap-
olations to a 5-year time horizon did not fully take into account the
development and management of long-term comorbidities and
differences in quality of life. However, we believe that our assump-
tions were conservative and favored OSR (eg, no follow-up cost or
need for re-intervention in OSR patients).
To evaluate the long-term cost-effectiveness of EVAR and
OSR in Canada, the authors recently developed a 10-year Markov
model based on a systematic literature review and Canadian cost
data. Based on commonly cited threshold, EVARwas not found to
be cost-effective compared with OSR.2 However, this study, like
other previous economic studies, was based on data from a mixed
population of low- and high-risk patients. As such, these findings
may not be generalizable to high-risk patients.
We also recently published a review aimed at evaluating trends
over time in EVAR vs OSR. Included in this review were 84
comparative studies (57,645 patients) of which six were random-
ized trials and 78 were nonrandomized trials. Eight nonrandom-
ized comparative studies specifically examined only high-risk pa-
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